ProCE Banner Activity

Targeting TIGIT: Understanding New Approaches for Inhibiting the Immune Checkpoint Pathway

Podcast Episodes
Listen to Drs. Jyoti Patel and Diwakar Davar as they discuss the latest research on TIGIT, the exciting emerging target in immune checkpoint inhibitors.

Released: April 07, 2022

Expiration: April 06, 2023

No longer available for credit.

Share

Faculty

Diwakar Davar

Diwakar Davar, MD

Assistant Professor
Melanoma and Phase I Therapeutics
Division of Hematology/Oncology
Department of Medicine
University of Pittsburgh Hillman Cancer Center
Pittsburgh, Pennsylvania

Jyoti D. Patel

Jyoti D. Patel, MD

Professor of Medicine
Division of Hematology and Oncology
Medical Director for Thoracic Oncology
Assistant Director for Clinical Research
Associate Vice Chair of Clinical Research
Department of Medicine
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Genentech, a member of the Roche Group

Faculty Disclosure

Primary Author

Diwakar Davar, MD

Assistant Professor
Melanoma and Phase I Therapeutics
Division of Hematology/Oncology
Department of Medicine
University of Pittsburgh Hillman Cancer Center
Pittsburgh, Pennsylvania

Jyoti D. Patel, MD, has disclosed that she has received funds for research from AstraZeneca, and has been and advisor for Abbvie and Takeda.

Jyoti D. Patel, MD

Professor of Medicine
Division of Hematology and Oncology
Medical Director for Thoracic Oncology
Assistant Director for Clinical Research
Associate Vice Chair of Clinical Research
Department of Medicine
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, Illinois

Diwakar Davar, MD, has disclosed that he has received funds for research support from Arcus, CellSight Technologies, Checkmate Pharmaceuticals, GlaxoSmithKline/Tesaro, Immunocore, and Merck and consulting fees from Checkmate Pharmaceuticals, Finch, Shionogi, and Vedanta.